Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: Insights into the RANKL/NF-κB signaling pathway

Chen，Tingting1,7; Ai，Gaoxiang2; Liang，Guihong4,5; Zeng，Lingfeng3,4,5; Zhao，Di4,5; Liu，Jun5,6; Dou，Yaoxing3,4,5

2024-05-01

10.1016/j.biopha.2024.116523

Biomedicine and Pharmacotherapy   影响因子和分区

0753-3322

1950-6007

Inflammatory bowel disease is linked to a higher occurrence of bone loss. Oxyberberine can effectively improve experimental inflammatory bowel disease. However, no study has shown the effect of oxyberberine on inflammatory bowel disease induced bone loss. The present study was performed to investigate the role of oxyberberine in inflammatory bowel disease induced osteoporosis in chronic inflammatory bowel disease mice model. The inflammatory bowel disease mice were orally given two doses of oxyberberine daily. Blood, colon, and bone specimens were collected for biomarker assessments and histological examinations. Bone biomechanical properties and key proteins and genes involved in the receptor activator of nuclear factor kappa-B ligand/nuclear factor kappa-B signaling pathway were evaluated. Additionally, the binding characteristics of oxyberberine and receptor activator of nuclear factor kappa-B ligand were evaluated by in silico simulation. Results indicated that oxyberberine treatment significantly attenuated the macroscopic damage, colonic shortening, and histological injury from the colon. Furthermore, oxyberberine decreased serum inflammatory cytokine levels. The intervention with oxyberberine significantly mitigated the deterioration of bone mass, biomechanical properties, and microstructural parameters. Moreover, the upregulated osteoclast formation factors in model mice were significantly abolished by oxyberberine. In silico simulation results also showed that oxyberberine was firmly bound with target protein. Hence, our findings indicated that oxyberberine had the potential to mitigate inflammatory bowel disease induced inflammation in bone, inhibit osteoclast formation through regulating the receptor activator of nuclear factor kappa-B ligand/nuclear factor kappa-B signaling pathway, and might be a valuable approach in preventing bone loss associated with inflammatory bowel disease.

Inflammatory Bowel Disease Osteoclast Osteoporosis Oxyberberine RANKL/NF-κB pathway

SCI

英语

第一

2-s2.0-85189516723

Scopus

1.School of Medicine,Southern University of Science and Technology,Shenzhen,China
2.Institute of Animal Husbandry and Veterinary Science,Jiangxi Academy of Agricultural Sciences,Nanchang,China
3.State Key Laboratory of Traditional Chinese Medicine Syndrome/The Second Clinical Medical College of Guangzhou University of Chinese Medicine/Post-Doctoral Research Station,Guangzhou,China
4.The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine),Guangzhou,China
5.Bone and Joint Research Team of Degeneration and Injury,Guangdong Provincial Academy of Chinese Medical Sciences,Guangzhou,China
6.Guangdong Second Traditional Chinese Medicine Hospital (Guangdong Province Engineering Technology Research Institute of Traditional Chinese Medicine),Guangzhou,China
7.Southern University of Science and Technology Hospital,Shenzhen,China

Chen，Tingting,Ai，Gaoxiang,Liang，Guihong,et al. Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: Insights into the RANKL/NF-κB signaling pathway[J]. Biomedicine and Pharmacotherapy,2024,174.

Chen，Tingting.,Ai，Gaoxiang.,Liang，Guihong.,Zeng，Lingfeng.,Zhao，Di.,...&Dou，Yaoxing.(2024).Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: Insights into the RANKL/NF-κB signaling pathway.Biomedicine and Pharmacotherapy,174.

Chen，Tingting,et al."Mitigation of inflammatory bowel disease-related osteoporosis by oxyberberine: Insights into the RANKL/NF-κB signaling pathway".Biomedicine and Pharmacotherapy 174(2024).